Discovery/R&D
-
Pragmatic Computational Biology with Andrew Satz
9/20/2023
This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?
-
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
2/12/2024
The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.
-
Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing
2/8/2021
Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.
-
IDO Target Perseverence With IO Biotech's Mai-Britt Zocca, Ph.D.
9/13/2022
Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech is advancing novel, immune-modulating cancer therapies targeting IDO (indoleamine 2,3-dioxygenase). Though promising, the target fell out of favor after some high-profile misses – most notably Merck's Phase 3 failure with pembrolizumab in 2018. But Immunome's dual mechanism of action is renewing interest in the target, and Dr. Zocca is gaining confidence as the company's data grows. On this episode of the Business of Biotech, she shares the approach, how it differs from previous attempts, and how her company is working to advance its programs in the wake of IDO's fall from grace.
-
Multimodal R&D Management With Incyte's Jim Lee, M.D., Ph.D.
1/18/2024
Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies.
-
Epigenomic Programming With Omega Therapeutics' Mahesh Karande
9/21/2022
Using computational biology to hasten the effort, Omega Therapeutics' plan is to "coopt nature's universal biological operating system for gene control and cell differentiation." On this episode of the Business of Biotech, we dig into exactly what that means. We also explore the company's preclinical ambitions, which are diverse, targeting regenerative, multigenic/immunologic, oncologic, and monogenic indications. Omega is leaning heavily into computational biology along the way, having mapped what CEO Mahesh Karande characterizes as 95% of the IGD landscape. Learn how Karande intends to maintain momentum on this episode of the Business of Biotech.
-
Bioengineering Human Tissue With Humacyte's Dr. Heather Prichard
1/5/2022
Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue.
-
Gynecological Cancer Therapies With Context Therapeutics' Martin Lehr
4/18/2022
Context Therapeutics Co-Founder & CEO Martin Lehr shares stories from his self-described "recovery from venture capital," the work his company is doing in gynecological cancers, and how his small company manages a modality-agnostic approach and investigator-sponsored trials across multiple clinical candidates, four of which are in phase 2 clinical trials. We also discuss his "extracurricular" work with BioBreak, Life Science Leader, and Life Science Cares, and why those organizations are important to him personally and professionally.
-
Changing The Diabetes Care Paradigm With Arecor's Dr. Sarah Howell
7/21/2022
While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago. Working with manufacturers of existing diabetes therapeutics in addition to advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide.
-
Off-The-Shelf CAR T-Cell Therapy?
10/26/2020
Find out what drove John McKearn, Ph.D. & CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-Cell leukemias and lymphomas, Acute Myeloid Leukemia, and Multiple Myeloma.